Blocking dietary TAG absorption and resynthesis in the intestinal lumen has been seen as a viable pathway in which to design small molecules targeting obesity and metabolic syndrome; inhibitors to the intestinal lipase (e.g., orlistat) are currently one of the few medicines available on the market, and inhibitors to DGAT1 are currently in clinical trials. Here, DGAT1 is linked to obesity disorder.